1. Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta‐analysis
- Author
-
Alaa Shalaby, Evan Adelstein, Aliza Hussain, Andrew Voigt, Andrew D. Althouse, Norman C. Wang, William E. Katz, Samir Saba, Matthew D. Sather, and Sandeep Jain
- Subjects
medicine.medical_specialty ,Heart Diseases ,medicine.drug_class ,Administration, Oral ,030204 cardiovascular system & hematology ,Dabigatran ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Heart Atria ,030212 general & internal medicine ,Rivaroxaban ,business.industry ,Remission Induction ,Warfarin ,Anticoagulants ,Thrombosis ,Atrial fibrillation ,General Medicine ,Vitamin K antagonist ,medicine.disease ,Confidence interval ,Atrial Flutter ,Meta-analysis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Atrial flutter ,medicine.drug - Abstract
BACKGROUND Oral anticoagulation (OAC) is prescribed for left atrial thrombi (LAT) in nonrheumatic atrial fibrillation (AF) and/or atrial flutter (AFL). The study objective was to review the existing evidence regarding LAT resolution in nonrheumatic AF and/or AFL with OAC agents. METHODS Data sources included PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) between January 1, 1991 and February 10, 2017. English-language studies that assessed LAT resolution with OAC agents in subjects with nonrheumatic AF and/or AFL, by serial transesophageal echocardiography, and with follow-up times ≥ 3 weeks and
- Published
- 2018